Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Mar 1;76(3 Suppl):S86-93.
doi: 10.1016/j.ijrobp.2009.05.070.

Radiation dose-volume effects in the esophagus

Affiliations
Review

Radiation dose-volume effects in the esophagus

Maria Werner-Wasik et al. Int J Radiat Oncol Biol Phys. .

Abstract

Publications relating esophageal radiation toxicity to clinical variables and to quantitative dose and dose-volume measures derived from three-dimensional conformal radiotherapy for non-small-cell lung cancer are reviewed. A variety of clinical and dosimetric parameters have been associated with acute and late toxicity. Suggestions for future studies are presented.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: none.

Figures

Fig. 1
Fig. 1
Correlations between acute esophagitis and Vx values (volume greater than x Gy). p Values correlated with relative or absolute volumes (in cubic centimeters); relative volumes used except as noted for 2006 data from Wei et al. (22). Lower values indicate better correlations with outcomes. As the wide variety of correlation shapes suggests, there does not appear to be any singular “threshold” dose above which a toxic effect is observed.
Fig. 2
Fig. 2
Incidence of acute esophagitis according to Vx (volume receiving more than x Gy). x-Axis values estimated according to range of doses reported. Each curve annotated as follows: Vdose (investigator, number of patients, percentage with concurrent chemotherapy [CCT]. Percentage of patients who received sequential chemotherapy in studies by Ahn et al. (11), Belderbos et al. (19), and Kim et al. (20) was 44%, 38%, and 15%, respectively. Data for V50 (Ahn et al. [11]) at 15, 45, and 75 Gy represent reported rates of Grade 2 or greater acute esophagitis plotted in dose bins at <30%, 30–60%, and >60%, respectively. Similarly, for V70 (Ahn et al. [11]), V50 (Rodriguez et al. [23]), and V60 (Kim et al. [20]), each symbol represents rates of acute esophagitis at <10% vs. 11–30% vs. 31–64%, and ≤30% vs. ≥30%, and ≤30 vs. >30%, respectively. Dashed horizontal lines reflect dose ranges ascribed to each data point. Upper x-axis range of greatest data point for V50 (Rodriguez et al. [23]), V50 (Ahn et al. [11]), and V60 (Kim et al. [20]), are indefinite according to data (light-gray dotted bars). Solid and open symbols represent reported rates of Grade 2 or greater acute esoph-agitis and Grade 3 or greater acute esophagitis, respectively. Thicker and thinner solid lines represent higher and lower doses of Vx, respectively (i.e., thicker line for V70 and thinner line for V20).

Similar articles

Cited by

References

    1. Curran W, Jr, Scott C, Langer C, et al. Phase III comparison of sequential vs. concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer: Initial report of RTOG 9410. Proc ASCO. 2000;19:484a.
    1. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent vs. sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol. 1999;17:2692–2699. - PubMed
    1. Cox JD, Pajak TF, Asbell S, et al. Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: Analysis of 1244 cases from 3 RTOG trials. Int J Radiat Oncol Biol Phys. 1993;27:493–498. - PubMed
    1. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancers. J Clin Oncol. 2006;24:4833–4839. - PubMed
    1. Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study. J Thoracic Oncol. 2007;2(7 Suppl 3):S94–S100. - PubMed